Replies to post #44613 on MindMaze Therapeutics Holding (RLFTF)

[Joe Kaplan]

https://twitter.com/search?q=Relief%20Therapeutics&src=typed_query&f=live

GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms to benefit the lives of patients living with rare diseases, today announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities. The medical affairs team will report to Paolo Galfetti, chief operating officer at Relief Therapeutics, until a replacement is hired. Clinical development and regulatory responsibilities will continue to be supported by consultants already contracted with the Company.

"We have established strong medical affairs and research and development teams that will continue to serve us well as we focus our resources to advance our metabolic, connective tissue and pulmonary rare disease programs forward," said Jack Weinstein, chief executive officer at Relief Therapeutics. "We have moved our pipeline through several important milestones over the past year, and we appreciate Nermeen's contributions to those efforts. We wish Nermeen success in her future endeavors."

[rollup]

PennyWorld & friends, look closely at the FirstString link - https://www.crunchbase.com/organization/firststring-research Now https://xequel.com/
in 2016 a lot of "changes" were made by existing a) Relief Therapeutic and b) Relief Therapeutic HOLDING SA............Best short comment on this on SW."...................

In July 2016 THERAMetrics holding AG combined its business with Relief Therapeutics SA, moved its legal seat from Stans to Zurich, and changed its name to Relief Therapeutics Holding AG. During this transformation, in June 2016 the Company exited the CRO (contract research organization) business by selling its significant contract research subsidiaries to a larger global CRO. The Company's smaller CRO subsidiaries, where there was little or no business, were closed. I think one of those subsidiaries became FirstString Research, later changing its name to Xequel Bio. I don't know the full details of the changes because they are still private.


Translated with www.DeepL.com/Translator (free version)